Shortwave Life Sciences is a UK-listed biopharmaceutical company pioneering a new model for advancing mental health treatments. With a focus on high-impact and high-unmet-need conditions, beginning with anorexia nervosa, Shortwave combines clinical innovation with a unique Digital Asset Treasury (DAT) strategy to accelerate development and build long-term financial resilience. Our approach addresses two of the biggest challenges in life sciences: access to capital and time to market. By strategically deploying part of our resources into regulated digital assets, we generate alternative revenue streams that help fund early-stage trials, reduce dilution, and retain world-class talent. This dual engine of science and strategy positions Shortwave to lead in a rapidly changing pharmaceutical and financial landscape. With our first feasibility trial underway at a global research institution and a growing team of clinical and digital asset experts, Shortwave offers a platform designed for scale, sustainability and long-term value creation.

Ambio Life Sciences is the global leader in integrative ibogaine treatment, setting a new benchmark for clinical quality, patient safety, and therapeutic innovation. With over 50 years of combined experience, Ambio’s founding team brings together unmatched expertise in medical protocols, research leadership, and ethical ibogaine care. Operating world-class clinics in Mexico and Malta, Ambio delivers medically supervised programs for addiction, traumatic brain injury, psychological trauma, chronic pain, and neurodegenerative conditions. The company also works with high-performance individuals – including special operations veterans, elite athletes, and creative professionals – seeking sustainable personal optimization and recovery from medically complex conditions. As the world’s only transcontinental and integrative ibogaine provider, we help individuals create lasting, adaptive change in their lives. Driven by science and grounded in deep clinical experience, Ambio is advancing a new paradigm in mental health and recovery, one that empowers individuals to reclaim agency and lead more adaptive, meaningful lives.

At every phase of the business lifecycle, from entrepreneurial startup to multi-national corporation, FTI Consulting offers the emerging medicines industry a suite of solutions and services that address specific business challenges around regulatory compliance, financial and operational discipline, business disputes, mergers and acquisitions, brand integrity and reputational enhancement.